Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [12953]

Radiation-induced cellular changes may mimic cancer recurrence in pap smears

Radiation-induced cellular changes may mimic cancer recurrence in pap smears

Study identifies immune switch critical to autoimmunity and cancer

Study identifies immune switch critical to autoimmunity and cancer

$SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain endocrine therapy-refractory advanced breast cancers$

SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain...

SABCS 2025: A multimodal AI model may improve recurrence risk stratification in early breast cancer

SABCS 2025: A multimodal AI model may improve recurrence risk stratification in early breast cancer

SABCS 2025: Adding tucatinib to first-line maintenance therapy delayed disease progression in HER2-positive metastatic breast cancer in HER2CLIMB-05 trial

SABCS 2025: Adding tucatinib to first-line maintenance therapy delayed disease progression in HER2-positive...

Study captures how cancer cells hide from brain immune cells, shows that removing their “don’t eat me” signals stops their escape

Study captures how cancer cells hide from brain immune cells, shows that removing their “don’t eat me” signals...

SABCS 2025: Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer

SABCS 2025: Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer

Targeting collagen signaling boosts drug delivery in pancreatic cancer

Targeting collagen signaling boosts drug delivery in pancreatic cancer

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

ASH 2025: Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

More from ecancer